CN110720628A - 一种保护化疗损伤肠黏膜屏障功能专用型临床营养配方及其制备方法 - Google Patents
一种保护化疗损伤肠黏膜屏障功能专用型临床营养配方及其制备方法 Download PDFInfo
- Publication number
- CN110720628A CN110720628A CN201911083249.2A CN201911083249A CN110720628A CN 110720628 A CN110720628 A CN 110720628A CN 201911083249 A CN201911083249 A CN 201911083249A CN 110720628 A CN110720628 A CN 110720628A
- Authority
- CN
- China
- Prior art keywords
- chemotherapy
- powder
- intestinal mucosa
- calcium
- barrier function
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000004347 intestinal mucosa Anatomy 0.000 title claims abstract description 42
- 230000004888 barrier function Effects 0.000 title claims abstract description 41
- 235000016709 nutrition Nutrition 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 230000035764 nutrition Effects 0.000 title claims abstract description 11
- 235000013305 food Nutrition 0.000 claims abstract description 19
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims abstract description 16
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 14
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 13
- 229940088594 vitamin Drugs 0.000 claims abstract description 13
- 229930003231 vitamin Natural products 0.000 claims abstract description 13
- 235000013343 vitamin Nutrition 0.000 claims abstract description 13
- 239000011782 vitamin Substances 0.000 claims abstract description 13
- 239000006041 probiotic Substances 0.000 claims abstract description 11
- 235000018291 probiotics Nutrition 0.000 claims abstract description 11
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 9
- 239000011707 mineral Substances 0.000 claims abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 9
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 8
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 8
- 229910052742 iron Inorganic materials 0.000 claims abstract description 8
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000011575 calcium Substances 0.000 claims abstract description 7
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 7
- 239000011701 zinc Substances 0.000 claims abstract description 7
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 7
- 150000001875 compounds Chemical class 0.000 claims abstract description 6
- 235000013325 dietary fiber Nutrition 0.000 claims abstract description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000011777 magnesium Substances 0.000 claims abstract description 4
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 4
- 239000011734 sodium Substances 0.000 claims abstract description 4
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 4
- 150000003722 vitamin derivatives Chemical class 0.000 claims abstract description 4
- 239000002131 composite material Substances 0.000 claims abstract description 3
- 239000000843 powder Substances 0.000 claims description 49
- 238000002512 chemotherapy Methods 0.000 claims description 23
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 18
- 238000002156 mixing Methods 0.000 claims description 17
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 230000006378 damage Effects 0.000 claims description 14
- 235000018102 proteins Nutrition 0.000 claims description 12
- 239000003094 microcapsule Substances 0.000 claims description 11
- 239000002994 raw material Substances 0.000 claims description 9
- 241000894006 Bacteria Species 0.000 claims description 8
- 229920002774 Maltodextrin Polymers 0.000 claims description 8
- 239000005913 Maltodextrin Substances 0.000 claims description 8
- 235000012754 curcumin Nutrition 0.000 claims description 8
- 239000004148 curcumin Substances 0.000 claims description 8
- 229940109262 curcumin Drugs 0.000 claims description 8
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims description 8
- 235000019197 fats Nutrition 0.000 claims description 8
- 230000001965 increasing effect Effects 0.000 claims description 8
- 229940035034 maltodextrin Drugs 0.000 claims description 8
- 235000010755 mineral Nutrition 0.000 claims description 8
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims description 7
- 208000027418 Wounds and injury Diseases 0.000 claims description 7
- 208000014674 injury Diseases 0.000 claims description 7
- 230000000529 probiotic effect Effects 0.000 claims description 7
- 239000004475 Arginine Substances 0.000 claims description 6
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 6
- 235000009697 arginine Nutrition 0.000 claims description 6
- 229960003121 arginine Drugs 0.000 claims description 6
- 229960005069 calcium Drugs 0.000 claims description 6
- 235000014633 carbohydrates Nutrition 0.000 claims description 6
- 229960003975 potassium Drugs 0.000 claims description 6
- 239000011591 potassium Substances 0.000 claims description 6
- 229910052700 potassium Inorganic materials 0.000 claims description 6
- 238000005303 weighing Methods 0.000 claims description 6
- 102000007544 Whey Proteins Human genes 0.000 claims description 5
- 108010046377 Whey Proteins Proteins 0.000 claims description 5
- WLJUMPWVUPNXMF-UHFFFAOYSA-L calcium;3-hydroxy-3-methylbutanoate Chemical compound [Ca+2].CC(C)(O)CC([O-])=O.CC(C)(O)CC([O-])=O WLJUMPWVUPNXMF-UHFFFAOYSA-L 0.000 claims description 5
- 238000007599 discharging Methods 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 238000010298 pulverizing process Methods 0.000 claims description 5
- 238000007873 sieving Methods 0.000 claims description 5
- 238000001694 spray drying Methods 0.000 claims description 5
- 235000021119 whey protein Nutrition 0.000 claims description 5
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims description 4
- 229920002498 Beta-glucan Polymers 0.000 claims description 4
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 4
- 241000196324 Embryophyta Species 0.000 claims description 4
- 235000010469 Glycine max Nutrition 0.000 claims description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 4
- 229930064664 L-arginine Natural products 0.000 claims description 4
- 235000014852 L-arginine Nutrition 0.000 claims description 4
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 4
- 108010038807 Oligopeptides Proteins 0.000 claims description 4
- 102000015636 Oligopeptides Human genes 0.000 claims description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 4
- HLCFGWHYROZGBI-JJKGCWMISA-M Potassium gluconate Chemical compound [K+].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O HLCFGWHYROZGBI-JJKGCWMISA-M 0.000 claims description 4
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 claims description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 4
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 4
- 229940009289 bifidobacterium lactis Drugs 0.000 claims description 4
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 claims description 4
- 239000001354 calcium citrate Substances 0.000 claims description 4
- 229960004256 calcium citrate Drugs 0.000 claims description 4
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 4
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 4
- 210000003022 colostrum Anatomy 0.000 claims description 4
- 235000021277 colostrum Nutrition 0.000 claims description 4
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 4
- 235000013924 ferrous gluconate Nutrition 0.000 claims description 4
- 239000004222 ferrous gluconate Substances 0.000 claims description 4
- 229960001645 ferrous gluconate Drugs 0.000 claims description 4
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 4
- VRIVJOXICYMTAG-IYEMJOQQSA-L iron(ii) gluconate Chemical compound [Fe+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O VRIVJOXICYMTAG-IYEMJOQQSA-L 0.000 claims description 4
- 239000003921 oil Substances 0.000 claims description 4
- 235000019198 oils Nutrition 0.000 claims description 4
- 239000004224 potassium gluconate Substances 0.000 claims description 4
- 235000013926 potassium gluconate Nutrition 0.000 claims description 4
- 229960003189 potassium gluconate Drugs 0.000 claims description 4
- 235000013337 tricalcium citrate Nutrition 0.000 claims description 4
- 239000011670 zinc gluconate Substances 0.000 claims description 4
- 235000011478 zinc gluconate Nutrition 0.000 claims description 4
- 229960000306 zinc gluconate Drugs 0.000 claims description 4
- 241000186000 Bifidobacterium Species 0.000 claims description 3
- 241000186660 Lactobacillus Species 0.000 claims description 3
- 244000124853 Perilla frutescens Species 0.000 claims description 3
- 235000006040 Prunus persica var persica Nutrition 0.000 claims description 3
- 244000046146 Pueraria lobata Species 0.000 claims description 3
- 235000010575 Pueraria lobata Nutrition 0.000 claims description 3
- 239000000944 linseed oil Substances 0.000 claims description 3
- 235000021388 linseed oil Nutrition 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims description 2
- SUUWYOYAXFUOLX-ZBRNBAAYSA-N (2s)-2-aminobutanedioic acid;(2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O.OC(=O)[C@@H](N)CCCN=C(N)N SUUWYOYAXFUOLX-ZBRNBAAYSA-N 0.000 claims description 2
- KWTQSFXGGICVPE-UHFFFAOYSA-N 2-amino-5-(diaminomethylideneamino)pentanoic acid;hydron;chloride Chemical compound Cl.OC(=O)C(N)CCCN=C(N)N KWTQSFXGGICVPE-UHFFFAOYSA-N 0.000 claims description 2
- 241000251468 Actinopterygii Species 0.000 claims description 2
- 108010088751 Albumins Proteins 0.000 claims description 2
- 102000009027 Albumins Human genes 0.000 claims description 2
- 244000144730 Amygdalus persica Species 0.000 claims description 2
- 235000017166 Bambusa arundinacea Nutrition 0.000 claims description 2
- 235000017491 Bambusa tulda Nutrition 0.000 claims description 2
- 241001134770 Bifidobacterium animalis Species 0.000 claims description 2
- 241000186012 Bifidobacterium breve Species 0.000 claims description 2
- 241000283690 Bos taurus Species 0.000 claims description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 2
- 239000001736 Calcium glycerylphosphate Substances 0.000 claims description 2
- 241000208688 Eucommia Species 0.000 claims description 2
- PMVSDNDAUGGCCE-TYYBGVCCSA-L Ferrous fumarate Chemical compound [Fe+2].[O-]C(=O)\C=C\C([O-])=O PMVSDNDAUGGCCE-TYYBGVCCSA-L 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- 244000116699 Lactobacillus acidophilus NCFM Species 0.000 claims description 2
- 235000009195 Lactobacillus acidophilus NCFM Nutrition 0.000 claims description 2
- 241000093427 Lactobacillus fermentum CECT 5716 Species 0.000 claims description 2
- 241000254697 Lactobacillus rhamnosus HN001 Species 0.000 claims description 2
- 108010063045 Lactoferrin Proteins 0.000 claims description 2
- 102000010445 Lactoferrin Human genes 0.000 claims description 2
- 244000179886 Moringa oleifera Species 0.000 claims description 2
- 235000011347 Moringa oleifera Nutrition 0.000 claims description 2
- 235000004347 Perilla Nutrition 0.000 claims description 2
- 108010001441 Phosphopeptides Proteins 0.000 claims description 2
- 244000082204 Phyllostachys viridis Species 0.000 claims description 2
- 235000015334 Phyllostachys viridis Nutrition 0.000 claims description 2
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 claims description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 2
- 241000194017 Streptococcus Species 0.000 claims description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims description 2
- 239000005862 Whey Substances 0.000 claims description 2
- FMRLDPWIRHBCCC-UHFFFAOYSA-L Zinc carbonate Chemical compound [Zn+2].[O-]C([O-])=O FMRLDPWIRHBCCC-UHFFFAOYSA-L 0.000 claims description 2
- CANRESZKMUPMAE-UHFFFAOYSA-L Zinc lactate Chemical compound [Zn+2].CC(O)C([O-])=O.CC(O)C([O-])=O CANRESZKMUPMAE-UHFFFAOYSA-L 0.000 claims description 2
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 claims description 2
- FRHBOQMZUOWXQL-UHFFFAOYSA-L ammonium ferric citrate Chemical compound [NH4+].[Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FRHBOQMZUOWXQL-UHFFFAOYSA-L 0.000 claims description 2
- 229940114079 arachidonic acid Drugs 0.000 claims description 2
- 235000021342 arachidonic acid Nutrition 0.000 claims description 2
- 239000011425 bamboo Substances 0.000 claims description 2
- 229940118852 bifidobacterium animalis Drugs 0.000 claims description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 2
- 229960003563 calcium carbonate Drugs 0.000 claims description 2
- 235000010216 calcium carbonate Nutrition 0.000 claims description 2
- 239000001110 calcium chloride Substances 0.000 claims description 2
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 2
- 229960002713 calcium chloride Drugs 0.000 claims description 2
- 235000011148 calcium chloride Nutrition 0.000 claims description 2
- 239000004227 calcium gluconate Substances 0.000 claims description 2
- 235000013927 calcium gluconate Nutrition 0.000 claims description 2
- 229960004494 calcium gluconate Drugs 0.000 claims description 2
- UHHRFSOMMCWGSO-UHFFFAOYSA-L calcium glycerophosphate Chemical compound [Ca+2].OCC(CO)OP([O-])([O-])=O UHHRFSOMMCWGSO-UHFFFAOYSA-L 0.000 claims description 2
- 229940095618 calcium glycerophosphate Drugs 0.000 claims description 2
- 235000019299 calcium glycerylphosphate Nutrition 0.000 claims description 2
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 claims description 2
- 239000001527 calcium lactate Substances 0.000 claims description 2
- 235000011086 calcium lactate Nutrition 0.000 claims description 2
- 229960002401 calcium lactate Drugs 0.000 claims description 2
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 claims description 2
- 239000000292 calcium oxide Substances 0.000 claims description 2
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 claims description 2
- 229940087373 calcium oxide Drugs 0.000 claims description 2
- 235000012255 calcium oxide Nutrition 0.000 claims description 2
- 239000001506 calcium phosphate Substances 0.000 claims description 2
- 229940095672 calcium sulfate Drugs 0.000 claims description 2
- 235000011132 calcium sulphate Nutrition 0.000 claims description 2
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 claims description 2
- 239000010495 camellia oil Substances 0.000 claims description 2
- 239000005018 casein Substances 0.000 claims description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 2
- 235000021240 caseins Nutrition 0.000 claims description 2
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 claims description 2
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 2
- 229940090949 docosahexaenoic acid Drugs 0.000 claims description 2
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 2
- 235000008524 evening primrose extract Nutrition 0.000 claims description 2
- 239000010475 evening primrose oil Substances 0.000 claims description 2
- 229940089020 evening primrose oil Drugs 0.000 claims description 2
- 229960004642 ferric ammonium citrate Drugs 0.000 claims description 2
- 229960002413 ferric citrate Drugs 0.000 claims description 2
- 239000011706 ferric diphosphate Substances 0.000 claims description 2
- 235000007144 ferric diphosphate Nutrition 0.000 claims description 2
- CADNYOZXMIKYPR-UHFFFAOYSA-B ferric pyrophosphate Chemical compound [Fe+3].[Fe+3].[Fe+3].[Fe+3].[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O CADNYOZXMIKYPR-UHFFFAOYSA-B 0.000 claims description 2
- 229940036404 ferric pyrophosphate Drugs 0.000 claims description 2
- 239000011773 ferrous fumarate Substances 0.000 claims description 2
- 235000002332 ferrous fumarate Nutrition 0.000 claims description 2
- 229960000225 ferrous fumarate Drugs 0.000 claims description 2
- 229960001781 ferrous sulfate Drugs 0.000 claims description 2
- 239000011790 ferrous sulphate Substances 0.000 claims description 2
- 235000003891 ferrous sulphate Nutrition 0.000 claims description 2
- 235000021323 fish oil Nutrition 0.000 claims description 2
- 229930003944 flavone Natural products 0.000 claims description 2
- 150000002212 flavone derivatives Chemical class 0.000 claims description 2
- 235000011949 flavones Nutrition 0.000 claims description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims description 2
- 239000004313 iron ammonium citrate Substances 0.000 claims description 2
- 235000000011 iron ammonium citrate Nutrition 0.000 claims description 2
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 claims description 2
- 229910000359 iron(II) sulfate Inorganic materials 0.000 claims description 2
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 claims description 2
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims description 2
- 229940039696 lactobacillus Drugs 0.000 claims description 2
- 229940078795 lactoferrin Drugs 0.000 claims description 2
- 235000021242 lactoferrin Nutrition 0.000 claims description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 2
- 239000004006 olive oil Substances 0.000 claims description 2
- 235000008390 olive oil Nutrition 0.000 claims description 2
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims description 2
- 239000001103 potassium chloride Substances 0.000 claims description 2
- 235000011164 potassium chloride Nutrition 0.000 claims description 2
- 239000001508 potassium citrate Substances 0.000 claims description 2
- 229960002635 potassium citrate Drugs 0.000 claims description 2
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 claims description 2
- 235000011082 potassium citrates Nutrition 0.000 claims description 2
- 229940071440 soy protein isolate Drugs 0.000 claims description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 2
- 235000019731 tricalcium phosphate Nutrition 0.000 claims description 2
- 229940078499 tricalcium phosphate Drugs 0.000 claims description 2
- 229910000391 tricalcium phosphate Inorganic materials 0.000 claims description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 2
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 claims description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims description 2
- 235000008939 whole milk Nutrition 0.000 claims description 2
- 239000004246 zinc acetate Substances 0.000 claims description 2
- 229960000314 zinc acetate Drugs 0.000 claims description 2
- 235000013904 zinc acetate Nutrition 0.000 claims description 2
- 239000011667 zinc carbonate Substances 0.000 claims description 2
- 235000004416 zinc carbonate Nutrition 0.000 claims description 2
- 229910000010 zinc carbonate Inorganic materials 0.000 claims description 2
- 229940043825 zinc carbonate Drugs 0.000 claims description 2
- 239000011746 zinc citrate Substances 0.000 claims description 2
- 235000006076 zinc citrate Nutrition 0.000 claims description 2
- 229940068475 zinc citrate Drugs 0.000 claims description 2
- 229940071566 zinc glycinate Drugs 0.000 claims description 2
- 239000011576 zinc lactate Substances 0.000 claims description 2
- 235000000193 zinc lactate Nutrition 0.000 claims description 2
- 229940050168 zinc lactate Drugs 0.000 claims description 2
- 239000011787 zinc oxide Substances 0.000 claims description 2
- 229960001296 zinc oxide Drugs 0.000 claims description 2
- 235000014692 zinc oxide Nutrition 0.000 claims description 2
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims description 2
- 229960001763 zinc sulfate Drugs 0.000 claims description 2
- 229910000368 zinc sulfate Inorganic materials 0.000 claims description 2
- UOXSXMSTSYWNMH-UHFFFAOYSA-L zinc;2-aminoacetate Chemical compound [Zn+2].NCC([O-])=O.NCC([O-])=O UOXSXMSTSYWNMH-UHFFFAOYSA-L 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 12
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 239000003792 electrolyte Substances 0.000 abstract description 3
- 208000030159 metabolic disease Diseases 0.000 abstract description 3
- 235000003715 nutritional status Nutrition 0.000 abstract description 3
- 208000024891 symptom Diseases 0.000 abstract description 3
- 230000000968 intestinal effect Effects 0.000 description 22
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 19
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 12
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 10
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 210000001035 gastrointestinal tract Anatomy 0.000 description 9
- 229930003316 Vitamin D Natural products 0.000 description 7
- 235000005911 diet Nutrition 0.000 description 7
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 7
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 235000019166 vitamin D Nutrition 0.000 description 7
- 239000011710 vitamin D Substances 0.000 description 7
- 150000003710 vitamin D derivatives Chemical class 0.000 description 7
- 229940046008 vitamin d Drugs 0.000 description 7
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 6
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 6
- 210000005027 intestinal barrier Anatomy 0.000 description 6
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 6
- 229960002477 riboflavin Drugs 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 5
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 5
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 229930003268 Vitamin C Natural products 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 239000002158 endotoxin Substances 0.000 description 5
- 239000003925 fat Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 229960003284 iron Drugs 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 210000004379 membrane Anatomy 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 235000019154 vitamin C Nutrition 0.000 description 5
- 239000011718 vitamin C Substances 0.000 description 5
- 229940045997 vitamin a Drugs 0.000 description 5
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 4
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 4
- 229930003451 Vitamin B1 Natural products 0.000 description 4
- 229930003471 Vitamin B2 Natural products 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 229960000304 folic acid Drugs 0.000 description 4
- 235000019152 folic acid Nutrition 0.000 description 4
- 239000011724 folic acid Substances 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000007358 intestinal barrier function Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 229960003495 thiamine Drugs 0.000 description 4
- 235000019155 vitamin A Nutrition 0.000 description 4
- 239000011719 vitamin A Substances 0.000 description 4
- 235000010374 vitamin B1 Nutrition 0.000 description 4
- 239000011691 vitamin B1 Substances 0.000 description 4
- 235000019164 vitamin B2 Nutrition 0.000 description 4
- 239000011716 vitamin B2 Substances 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 244000068988 Glycine max Species 0.000 description 3
- 208000010718 Multiple Organ Failure Diseases 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- LXNHXLLTXMVWPM-UHFFFAOYSA-N Vitamin B6 Natural products CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000004673 intestinal mucosal barrier function Effects 0.000 description 3
- 150000004668 long chain fatty acids Chemical class 0.000 description 3
- 210000003563 lymphoid tissue Anatomy 0.000 description 3
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 229960000342 retinol acetate Drugs 0.000 description 3
- 235000019173 retinyl acetate Nutrition 0.000 description 3
- 239000011770 retinyl acetate Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019158 vitamin B6 Nutrition 0.000 description 3
- 239000011726 vitamin B6 Substances 0.000 description 3
- 235000005282 vitamin D3 Nutrition 0.000 description 3
- 239000011647 vitamin D3 Substances 0.000 description 3
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 3
- 229940011671 vitamin b6 Drugs 0.000 description 3
- 229940021056 vitamin d3 Drugs 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 2
- 244000163122 Curcuma domestica Species 0.000 description 2
- 235000003392 Curcuma domestica Nutrition 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 229930003779 Vitamin B12 Natural products 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000005549 barrier dysfunction Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- MKJXYGKVIBWPFZ-CEOVSRFSSA-L calcium;(2s)-2-hydroxypropanoate Chemical compound [Ca+2].C[C@H](O)C([O-])=O.C[C@H](O)C([O-])=O MKJXYGKVIBWPFZ-CEOVSRFSSA-L 0.000 description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 2
- 239000005516 coenzyme A Substances 0.000 description 2
- 229940093530 coenzyme a Drugs 0.000 description 2
- 235000003373 curcuma longa Nutrition 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000003870 intestinal permeability Effects 0.000 description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 229940091250 magnesium supplement Drugs 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 2
- 229940055726 pantothenic acid Drugs 0.000 description 2
- 235000019161 pantothenic acid Nutrition 0.000 description 2
- 239000011713 pantothenic acid Substances 0.000 description 2
- 230000003071 parasitic effect Effects 0.000 description 2
- -1 phytosterols Chemical compound 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 235000019192 riboflavin Nutrition 0.000 description 2
- 239000002151 riboflavin Substances 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 229940083542 sodium Drugs 0.000 description 2
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 229960000344 thiamine hydrochloride Drugs 0.000 description 2
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 2
- 239000011747 thiamine hydrochloride Substances 0.000 description 2
- 210000001578 tight junction Anatomy 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 235000013976 turmeric Nutrition 0.000 description 2
- 235000018648 unbalanced nutrition Nutrition 0.000 description 2
- 235000019163 vitamin B12 Nutrition 0.000 description 2
- 239000011715 vitamin B12 Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- WFJIVOKAWHGMBH-UHFFFAOYSA-N 4-hexylbenzene-1,3-diol Chemical compound CCCCCCC1=CC=C(O)C=C1O WFJIVOKAWHGMBH-UHFFFAOYSA-N 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- JDLKFOPOAOFWQN-VIFPVBQESA-N Allicin Natural products C=CCS[S@](=O)CC=C JDLKFOPOAOFWQN-VIFPVBQESA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 244000247812 Amorphophallus rivieri Species 0.000 description 1
- 235000001206 Amorphophallus rivieri Nutrition 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010007733 Catabolic state Diseases 0.000 description 1
- 208000018380 Chemical injury Diseases 0.000 description 1
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 208000036649 Dysbacteriosis Diseases 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 206010014418 Electrolyte imbalance Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 230000035519 G0 Phase Effects 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 206010019670 Hepatic function abnormal Diseases 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 229920002752 Konjac Polymers 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 125000003338 L-glutaminyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C(=O)N([H])[H] 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 201000010927 Mucositis Diseases 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 235000004348 Perilla frutescens Nutrition 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 239000004260 Potassium ascorbate Substances 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 240000005809 Prunus persica Species 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 229920000294 Resistant starch Polymers 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 108010017898 Shiga Toxins Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000009056 active transport Effects 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- ANVAOWXLWRTKGA-XHGAXZNDSA-N all-trans-alpha-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1C(C)=CCCC1(C)C ANVAOWXLWRTKGA-XHGAXZNDSA-N 0.000 description 1
- 235000019169 all-trans-retinol Nutrition 0.000 description 1
- 229940100609 all-trans-retinol Drugs 0.000 description 1
- 239000011717 all-trans-retinol Substances 0.000 description 1
- 235000010081 allicin Nutrition 0.000 description 1
- JDLKFOPOAOFWQN-UHFFFAOYSA-N allicin Chemical compound C=CCSS(=O)CC=C JDLKFOPOAOFWQN-UHFFFAOYSA-N 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 150000005693 branched-chain amino acids Chemical class 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229940047036 calcium ascorbate Drugs 0.000 description 1
- 239000011692 calcium ascorbate Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000008971 epithelial apoptosis Effects 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 1
- 229940107187 fructooligosaccharide Drugs 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 1
- 150000003271 galactooligosaccharides Chemical class 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000009698 intestinal cell proliferation Effects 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000000252 konjac Substances 0.000 description 1
- 235000010485 konjac Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001518 levocarnitine Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000012866 low blood pressure Diseases 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229940078752 magnesium ascorbyl phosphate Drugs 0.000 description 1
- 239000001755 magnesium gluconate Substances 0.000 description 1
- 235000015778 magnesium gluconate Nutrition 0.000 description 1
- 229960003035 magnesium gluconate Drugs 0.000 description 1
- IAKLPCRFBAZVRW-XRDLMGPZSA-L magnesium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;hydrate Chemical compound O.[Mg+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O IAKLPCRFBAZVRW-XRDLMGPZSA-L 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 230000004682 mucosal barrier function Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000009057 passive transport Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229940068065 phytosterols Drugs 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 229940017794 potassium ascorbate Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 235000021254 resistant starch Nutrition 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000011755 sodium-L-ascorbate Substances 0.000 description 1
- 235000019187 sodium-L-ascorbate Nutrition 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- UIERGBJEBXXIGO-UHFFFAOYSA-N thiamine mononitrate Chemical compound [O-][N+]([O-])=O.CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N UIERGBJEBXXIGO-UHFFFAOYSA-N 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- HTJNEBVCZXHBNJ-XCTPRCOBSA-H trimagnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;diphosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O HTJNEBVCZXHBNJ-XCTPRCOBSA-H 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pediatric Medicine (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明公开了一种保护化疗损伤肠黏膜屏障功能专用型临床营养配方及其制备方法,包括如下重量份数的组分:3~6份脂肪、25~45份蛋白质、10~25份碳水化合物、12~25份膳食纤维、钠0.11~0.3份、钙0.1~0.2份、铁0.01~0.02份、锌0.01~0.02、镁0.01~0.02份、0.02‑0.3份复合维生素、0.5~5份药食同源成分、益生菌0.1~0.4份、0.1~1份天然植物化合物以及0.1~0.4份新资源食品。本发明提供的临床营养配方针对化疗损伤肠黏膜屏障患者搭配碳水化合物、蛋白质、脂肪的供给能量比值,选择多种维生素、矿物质、药食同源和新资源食品,减轻患者的临床症状,纠正水及电解质代谢紊乱,改善患者的营养状况,安全且无毒副作用。
Description
技术领域
本发明涉及特殊医学用途食品配方领域,尤其涉及一种保护化疗损伤肠黏膜屏障功能专用型临床营养配方及其制备方法。
背景技术
肠黏膜屏障功能是指肠道上皮具有分隔肠腔内容物质,防止肠腔内有害物质、致病性抗原侵入体内其他组织器官、血液循环和淋巴循环的结构和功能的总和。正常情况下,肠屏障可有效地阻挡肠腔内500多种浓度高达1012/g的寄生菌及其毒素向肠腔外组织、器官移位,防止机体受侵害。肠黏膜屏障主要包括机械屏障、生物屏障、化学屏障和免疫屏障。
机械屏障是指完整的彼此紧密连接的肠黏膜上皮结构;由肠黏膜上皮细胞、细胞间紧密连接、上皮基膜及上皮表面的菌膜共者共同构成。生物屏障主要由正常的肠道菌群构成,是对外来菌株有定植抵抗作用的肠内正常寄生菌群。胃肠道分泌的胃酸、胆汁、各种消化酶、溶菌酶、黏多糖、糖蛋白和糖脂等化学物质组成肠黏膜的化学屏障。具有灭活病原微生物的作用,并能通过润滑作用以保护肠黏膜免受物理化学损伤。肠道免疫屏障主要由肠道免疫系统的细胞群组成,包括肠黏膜淋巴组织(如Peyer结、肠系膜淋巴结)、细胞(如树突状细胞、巨噬细胞、T细胞、B细胞等)和肠黏膜表面的分泌型抗体。
任何引起肠黏膜屏障功能障碍的因素都可以加重原有疾病,甚至在其基础上诱发和(或)加重全身炎性反应综合征导致脓毒症、休克、多器官功能障碍综合征和多器官功能衰竭的发生,甚至死亡。
化疗是恶性肿瘤系统治疗的重要组成部分,化疗药物在杀伤肿瘤细胞的同时对正常的组织器官也有不同程度的影响,其中肠黏膜损伤正是某些抗癌药物的毒性反应。近年来,随着对肠黏膜屏障功能研究的深人,化疗时消化道不良反应不再仅限于恶心、呕吐、腹泻的研究,而是更多倾向于组织结构、微生态系统、黏膜免疫、细胞凋亡、细胞因子等方面来研究化疗时肠黏膜屏障的损伤。
化疗对肠黏膜屏障的损伤包括①直接损伤肠黏膜。②菌群失调。③损伤免疫功能。④引起上皮细胞凋亡。⑤影响细胞周期、阻碍肠黏膜修复。⑥肠-肝轴受损。
直接损伤肠黏膜,组织学主要表现为上皮细胞正常更新减慢,绒毛萎缩,吸收面积减少,吸收功能减弱,出现腹泻。
肠道菌群失衡加之肠屏障通透增加,使胃肠的细菌和内毒素易发生移位而侵入淋巴结、门静脉以及其他远处器官,引发肠源性感染。通过荧光定量PCR检测化疗急性淋巴细胞白血病患儿肠道菌群,提示化疗的患儿肠道中双歧杆菌、乳酸杆菌和大肠埃希菌的数量明显减少。
化疗可以导致肝功能受损,致使肝脏的免疫及清除毒素的能力下降,化疗引起肠黏膜屏障功能障碍时大量内毒素移位至肝脏,当超过肝清除能力极限时,大量内毒素使肝网状内皮系统出现暂时性吞噬能力下降,高浓度的内毒素可激活补体替代途径引发高热、低血压,活化凝血系统,鼓后导致弥漫性血管内凝血。
谷氨酰胺是血液内含量最丰富的氨基酸,占机体游离氨基酸的50%。谷氨酰胺池中75%存在于骨骼肌中,其余部分主要存在于肝内。创伤、分解代谢状态及肿瘤患者血液和组织中的谷氨酰胺下降,创伤等应激时,贮存的谷氨酰胺可能消耗50%以上,血浆浓度下降20%-30%,细胞内谷氨酰胺下降的结果导致自骨骼肌释放增加,宿主各组织谷氨酰胺下降。
谷氨酰胺是人体内快速增殖细胞的呼吸燃料,也是核酸、蛋白质合成的前体,在化疗引起的机体应激状态下为条件必需氨基酸其保护肠屏障机制与其有利于肠细胞增生有关,补充谷氨酰胺可减轻肠通透性,降低细菌毒素易位,减少肠源性感染发生。研究表明谷氨酸胺能明显减轻化疗导致的乳腺癌患者肠道通透性增加。
因此,研发一款能够针对化疗损伤肠黏膜屏障产生的副作用,帮助改善患者接受化疗后不良反应,并且无毒副作用的营养产品非常关键。
发明内容
本发明为解决现有技术中的上述问题,提供一种保护化疗损伤肠黏膜屏障功能专用型临床营养配方及其制备方法,针对化疗损伤黏膜屏障功能导致患者机体饮食结构不合理、营养不均衡等不良现状,主要是通过合理的膳食调配,搭配碳水化合物、蛋白质、脂肪的供给能量比值,选择多种维生素、矿物质、药食同源和新资源食品,减轻患者的临床症状,纠正水及电解质代谢紊乱,改善患者的营养状况,安全且无毒副作用。
为实现上述目的,本发明采用以下技术方案:
本发明的第一个方面是提供一种保护化疗损伤肠黏膜屏障功能专用型临床营养配方,包括如下重量份数的组分:3~6份脂肪、25~45份蛋白质、10~25份碳水化合物、12~25份膳食纤维、钠0.11~0.3份、钾0.1~0.2份、钙0.1~0.2份、铁0.01~0.02份、锌0.01~0.02、镁0.01~0.02份、0.02-0.3份复合维生素、0.5~5份药食同源成分、益生菌0.1~0.4份、0.1~1份天然植物化合物以及0.2~2份新资源食品;
所述天然植物化合物包括姜黄素和左旋肉碱;
所述新资源食品包括谷氨酰胺。
谷氨酰胺可能通过刺激肠黏膜IGF1、CLN和GLN合成酶mRNA表达,下调肠黏膜细胞凋亡,从而促进肠黏膜修复。有观点认为谷氨酰胺是肠黏膜上皮、淋巴组织等代谢旺盛细胞和组织的主要能源;谷氨酰胺为DNA和RNA的前体物质嘌呤及嘧啶的合成提供氮源,同时也是蛋白质合成的氮源。谷氨酰胺有促进蛋白质合成、抑制蛋白质分解的作用。谷氨酰胺可限制细胞因子的产生和中性多形核细胞的浸润,从而降低了该类细胞沿趋化梯度迁移所引起的细胞间紧密连接的通透性,起到保护肠黏膜结构和屏障的功能。通过补充能量和改善代谢来维持细胞器结构和功能的完整,保护黏膜细胞的超微结构免于受损。此外谷氨酰胺还能促进黏膜淋巴组织分泌S-IgA,降低细菌对黏膜的附着和定植,防止其穿越肠黏膜上皮细胞层,以减少细菌和内毒素的易位。
优选地,谷氨酰胺为L-谷氨酰胺。
优选地,所述天然植物化合物还包括左旋肉碱、氨基葡萄糖、叶黄素、植物甾醇、番茄红素、白藜芦醇、大蒜素中的一种或多种。
左旋肉碱在生物细胞内主要定位于线粒体的内膜,其功能是以载体形式即脂酸肉碱的形式将长链脂肪酸从线粒体膜外运送到膜内,促进脂肪酸的β-氧化:并起着调节酰基CoA/CoA比率的作用。左旋肉碱和它的酰基还是自由基的清除剂和铁的鳌合剂,具有抗氧化功能;作为长链脂肪酸的载体,参与膜修复过程中膜磷脂的去酰基-重酸化,有利于膜的及时修复,起到次级抗氧化防御屏障的作用;节约游离辅酶A,增加长链酰基辅酶A,恢复酰基酸转位酶的活性,稳定细胞膜,促进支链氨基酸的氧化利用等作用,对肠黏膜屏障具有一定的保护作用。
姜黄素是从姜黄中提取出来的一种酚类色素,也是姜黄的主要活性成分。大量研究表明姜黄素具有抗感染、抗炎、免疫调节、抗氧化、抗突变等生物学作用。姜黄素能通过增强MKP-l的磷酸化作用,抑制NF-KB和p38活性,进而减少致炎细胞因子TNF-a、IL-lβmRNA和ICAM-1表达,增强抑炎因子IL-10的表达来减轻肠黏膜炎症损伤;也可通过抑制p38、JNK和Nk-KB活性,减轻志贺样毒素与TNF-a诱导的HT-29细胞株的结合,减轻肠上皮细胞的死亡。由上可见,姜黄素对化疗大鼠肠黏膜屏障的保护作用。
优选地,所述新资源食品还包括精氨酸、β-羟基-β-甲基丁酸钙、初乳碱性蛋白、γ-氨基丁酸、壳寡糖、杜仲雄花、竹叶黄酮、酪蛋白磷酸肽、燕麦β-葡聚糖、酵母β-葡聚糖、辣木叶、低聚木糖中的一种或多种。
精氨酸可使肿瘤细胞从G0期进入S期的数量增多,在化疗时予以精氨酸可增强肿瘤细胞对化疗药物的敏感性,更大限度地杀伤肿瘤细胞。
进一步地,所述精氨酸选自L-精氨酸、L-盐酸精氨酸和L-精氨酸-天冬氨酸中的一种或多种。
更进一步地,新资源食品选择L-精氨酸和β-羟基-β-甲基丁酸钙。
优选地,所述蛋白质还包括水解乳清蛋白粉、浓缩乳清蛋白粉、大豆分离蛋白、全蛋粉、牛初乳、全脂奶粉、白蛋白肽、大豆肽、海洋鱼低聚肽、小麦低聚肽、玉米低聚肽粉、α-乳清蛋白粉、乳铁蛋白中的一种或多种。
补充丰富的高生物价优质蛋白质有益于人体消化吸收系统的吸收利用,全面均衡地补充人体所需的8种必须氨基酸,否则容易出现负氮平衡,提高免疫力。
优选地,所述膳食纤维选自菊粉、魔芋粉、低聚半乳糖、低聚果糖、低聚异麦芽糖、大豆多糖、环糊精、抗性糊精、大豆纤维中的一种或多种。
优选地,益生菌选自双歧杆菌属、乳杆菌属、链球菌属、嗜酸乳杆菌NCFM、动物双歧杆菌Bb-12、乳双歧杆菌HN019、乳双歧杆菌Bi-07、鼠李糖乳杆菌LGG、鼠李糖乳杆菌HN001、发酵乳杆菌CECT5716、短双歧杆菌M-16V中的一种或多种。
益生菌被称为微生态制剂或活菌制剂,指能在肠道生态系统中存活的正常菌群或具有调节和有益作用的外来菌。益生菌对肠屏障功能的保护作用机制如下:①定植拮抗作用。维持肠内菌群平衡,抑制致病菌繁殖。②促进肠道紧密连接相关蛋白表达。③改善肠道免疫功能,提高机体免疫功能。④及时清除肠道致癌物,促进抗癌物质释放,诱导肿瘤细胞凋亡。因此,及时补充益生菌,对在化疗期间肠道菌群失调引起的全身感染、全身炎性反应综合征、多器官功能障碍综合征的防治有重要意义。
进一步地,益生菌选择鼠李糖乳杆菌LGG。
化疗损伤肠黏膜屏障的患者中,矿物质(钾、钠、镁、钙、铁、锌)和维生素(维生素A、维生素D、维生素E、维生素B1、维生素B2、维生素B6、维生素B12、维生素C、烟酸、叶酸、泛酸)的大量丢失,导致电解质失衡。所以应及时予以补充。
优选地,所述复合维生素选自维生素A、维生素D、维生素E、维生素B1、维生素B2、维生素B6、维生素B12、维生素C、叶酸、泛酸中的一种或多种。
进一步地,所述维生素A选自醋酸视黄酯、棕榈酸视黄酯、全反式视黄醇、β-胡萝卜素中的一种或多种;维生素C选自L-抗坏血酸、L-抗坏血酸钙、维生素C磷酸酯镁、L-抗坏血酸钠、L-抗坏血酸钾、抗坏血酸棕榈酸酯中的一种或多种;维生素D选自麦角钙化醇、胆钙化醇中的一种或多种。膳食中富含维生素D的食物很少,因此要注意补充维生素D;所述维生素B1选自盐酸硫胺素、硝酸硫胺素中的一种或多种;所述维生素B2选自核黄素和核黄素-5’-磷酸钠中的一种或多种。
更进一步地,所述维生素A选择醋酸视黄酯;维生素C选择L-抗坏血酸钠;维生素D选择胆钙化醇;维生素B2选择核黄素;维生素B1选择盐酸硫胺素。
优选地,所述钙选自β-羟基-β-甲基丁酸钙、碳酸钙、葡萄糖酸钙、柠檬酸钙、L-乳酸钙、磷酸氢钙、氯化钙、磷酸三钙、甘油磷酸钙、氧化钙、硫酸钙中的一种或多种组成;所述钾选自葡萄糖酸钾、柠檬酸钾、磷酸二氢钾、磷酸氢二钾、氯化钾中的一种或多种;所述铁选自硫酸亚铁、葡萄糖酸亚铁、柠檬酸铁铵、富马酸亚铁、柠檬酸铁、焦磷酸铁中的一种或多种;所述锌选自葡萄糖酸锌、氧化锌、柠檬酸锌、硫酸锌、甘氨酸锌、乳酸锌、乙酸锌、碳酸锌中的一种或多种。
进一步地,所述钙选择柠檬酸钙、L-乳酸钙和磷酸氢钙;钾选择葡萄糖酸钾;铁选择葡萄糖酸亚铁;锌选择葡萄糖酸锌。
优选地,所述所述药食同源成分选自桃仁、紫苏和葛根中的一种或多种。
优选地,脂肪选自脂肪选自鱼油微囊粉、亚麻籽油微囊粉、月见草油微囊粉、橄榄油微囊粉、链甘油三酯粉、二十二碳六烯酸油脂粉、花生四烯酸油脂粉、茶油微囊粉中的一种或多种。
动物实验发现,膳食中给予n-3及n-6多不饱和脂肪酸可通过改变大鼠空肠上皮主动与被动转运能力,降低肠黏膜通透性,保护肠道屏障功能,同时抑制炎症细胞因子的表达,减轻肠粘膜损伤。
进一步地,所述脂肪中,不饱和脂肪酸n-6:n-3=4~6:1。
优选地,所述碳水化合物选自果糖、冰糖、乳糖、麦芽糊精、木薯淀粉、抗性淀粉中一种或多种。进一步地,所述碳水化合物选择麦芽糊精。
本发明还提供了一种上述保护化疗损伤肠黏膜屏障功能专用型临床营养配方的制备方法。
包括以下步骤:
(1)预定重量的药食同源成分通过粉碎、醇提、水提、喷雾干燥并过60-80目筛制成粉末;
(2)按照组分表称量其他各组分,维生素、矿物质、新资源食品原料和步骤(1)制得的粉末混合制备预混料,将预混料与2%麦芽糊精先混合10分钟;
(3)将其它物料按照逐级递增的原则投入混合机,混合20分钟,出料,得配方制剂。
进一步地,上述各原料均为粒径为50~200μm的粉末形式的原料,配置前及配置完成后均经过杀菌处理。
进一步地,所述营养配方的剂型包括营养粉、营养乳剂、胶囊剂、片剂、丸剂、口服液等。
本发明采用上述技术方案,与现有技术相比,具有如下技术效果:
本发明针对化疗损伤黏膜屏障功能导致患者机体饮食结构不合理、营养不均衡等不良现状,主要是通过合理的膳食调配,搭配碳水化合物、蛋白质、脂肪的供给能量比值,选择多种维生素、矿物质,改善患者的营养状况,同时选择多种益生菌、药食同源和新资源食品,减轻患者的临床症状,纠正水及电解质代谢紊乱。
采用无渣或少渣、易消化的要素饮食,最大限度地减少粪便体积,限制膳食纤维的摄入,减轻消化道负担。
具体实施方式
下面通过具体实施例对本发明进行详细和具体的介绍,以使更好的理解本发明,但是下述实施例并不限制本发明范围。
实施例1
本实施例中保护化疗损伤肠黏膜屏障功能专用型临床营养配方包括以下组分:
上述保护化疗损伤肠黏膜屏障功能专用型临床营养配方的制备方法,包括以下步骤:
(1)预定重量的药食同源成分通过粉碎、醇提、水提、喷雾干燥并过60-80目筛制成粉末;
(2)按照组分表称量其他各组分,各原料均为粒径为50~200μm的粉末形式,维生素、矿物质、新资源食品原料和步骤(1)制得的粉末混合制备预混料,将预混料与2%麦芽糊精先混合10分钟;
(3)将其它物料按照逐级递增的原则投入混合机,混合20分钟,出料,得配方制剂。
(4)制备成营养粉。
实施例2
本实施例中保护化疗损伤肠黏膜屏障功能专用型临床营养配方包括以下组分:
上述保护化疗损伤肠黏膜屏障功能专用型临床营养配方的制备方法,包括以下步骤:
(1)预定重量的药食同源成分通过粉碎、醇提、水提、喷雾干燥并过60-80目筛制成粉末;
(2)按照组分表称量其他各组分,各原料均为粒径为50~200μm的粉末形式,维生素、矿物质、新资源食品原料和步骤(1)制得的粉末混合制备预混料,将预混料与2%麦芽糊精先混合10分钟;
(3)将其它物料按照逐级递增的原则投入混合机,混合20分钟,出料,得配方制剂。
(4)制备成营养粉。
实施例3
本实施例中保护化疗损伤肠黏膜屏障功能专用型临床营养配方包括以下组分:
组成 | 重量(g) |
乳清蛋白粉 | 42.00 |
果糖 | 15.00 |
麦芽糊精 | 2.00 |
菊粉 | 5.00 |
抗性糊精 | 17.00 |
柠檬酸钙 | 0.40 |
L-乳酸钙 | 0.80 |
磷酸氢钙 | 0.20 |
葡萄糖酸钾 | 2.00 |
柠檬酸钠 | 2.00 |
葡萄糖酸镁 | 0.4 |
葡萄糖酸亚铁 | 0.16 |
葡萄糖酸锌 | 0.12 |
醋酸视黄酯(维生素A) | 0.01 |
胆钙化醇(维生素D) | 0.01 |
dl-α-生育酚(维生素E) | 0.02 |
盐酸硫胺素(维生素B1) | 0.01 |
核黄素(维生素B2) | 0.01 |
盐酸吡哆醇(维生素B6) | 0.01 |
氰钴胺(维生素B12) | 0.01 |
L-抗坏血酸钠(维生素C) | 0.10 |
D-泛酸钙 | 0.01 |
蝶酰谷氨酸(叶酸) | 0.01 |
烟酰胺(维生素B3) | 0.02 |
亚麻籽油微囊粉 | 4.00 |
左旋肉碱 | 0.15 |
姜黄素 | 0.02 |
β-羟基-β-甲基丁酸钙 | 0.8 |
L-精氨酸 | 0.05 |
鼠李糖乳杆菌LGG | 0.10 |
L-谷氨酰胺 | 0.5 |
桃仁 | 1.50 |
紫苏 | 1.50 |
葛根 | 1.50 |
上述保护化疗损伤肠黏膜屏障功能专用型临床营养配方的制备方法,包括以下步骤:
(1)预定重量的药食同源成分通过粉碎、醇提、水提、喷雾干燥并过60-80目筛制成粉末;
(2)按照组分表称量其他各组分,各原料均为粒径为50~200μm的粉末形式,维生素、矿物质、新资源食品原料和步骤(1)制得的粉末混合制备预混料,将预混料与2%麦芽糊精先混合10分钟;
(3)将其它物料按照逐级递增的原则投入混合机,混合20分钟,出料,得配方制剂。
(4)制备成营养粉。
应用实施例
选取身体条件状况相同的SD大鼠36只,随机分为空白组、对照组和实验组,每组12只。对照组与空白组实验组予以实施例1所述营养粉一日两次,一次100g,温水冲泡后灌胃,对照组和空白组予以等量淀粉糊灌胃。第4天后,对照组和实验组腹腔注射5-Fu(100mg/kg),空白组等量淀粉糊灌胃。再观察4天。
分别在实验第1d,4d,7d灌胃前称重并记录。称重结果如下表1(+:体重增加,-:体重减轻;)。
表1三组大鼠体重平均变化值
以上对本发明的具体实施例进行了详细描述,但其只是作为范例,本发明并不限制于以上描述的具体实施例。对于本领域技术人员而言,任何对本发明进行的等同修改和替代也都在本发明的范畴之中。因此,在不脱离本发明的精神和范围下所作的均等变换和修改,都应涵盖在本发明的范围内。
Claims (10)
1.一种保护化疗损伤肠黏膜屏障功能专用型临床营养配方,其特征在于,包括如下重量份数的组分:3~6份脂肪、25~45份蛋白质、10~25份碳水化合物、12~25份膳食纤维、钠0.11~0.3份、钾0.1~0.2份、钙0.1~0.2份、铁0.01~0.02份、锌0.01~0.02、镁0.01~0.02份、0.02-0.3份复合维生素、0.5~5份药食同源成分、益生菌0.1~0.4份、0.1~1份天然植物化合物以及0.2~2份新资源食品;
所述天然植物化合物包括姜黄素和左旋肉碱;
所述新资源食品包括谷氨酰胺。
2.根据权利要求1所述的保护化疗损伤肠黏膜屏障功能专用型临床营养配方,其特征在于,所述新资源食品还包括精氨酸、β-羟基-β-甲基丁酸钙、初乳碱性蛋白、γ-氨基丁酸、壳寡糖、杜仲雄花、竹叶黄酮、酪蛋白磷酸肽、燕麦β-葡聚糖、酵母β-葡聚糖、辣木叶、低聚木糖中的一种或多种。
3.根据权利要求2所述的保护化疗损伤肠黏膜屏障功能专用型临床营养配方,其特征在于,所述精氨酸选自L-精氨酸、L-盐酸精氨酸和L-精氨酸-天冬氨酸中的一种或多种。
4.根据权利要求1所述的保护化疗损伤肠黏膜屏障功能专用型临床营养配方,其特征在于,所述蛋白质选自水解乳清蛋白粉、大豆分离蛋白肽、全蛋粉、白蛋白肽、大豆肽、海洋鱼低聚肽、浓缩乳清蛋白粉、牛初乳粉、全脂奶粉、α-乳清蛋白粉、乳铁蛋白中的一种或多种。
5.根据权利要求1所述的保护化疗损伤肠黏膜屏障功能专用型临床营养配方,其特征在于,益生菌选自双歧杆菌属、乳杆菌属、链球菌属、嗜酸乳杆菌NCFM、动物双歧杆菌Bb-12、乳双歧杆菌HN019、乳双歧杆菌Bi-07、鼠李糖乳杆菌LGG、鼠李糖乳杆菌HN001、发酵乳杆菌CECT5716、短双歧杆菌M-16V中的一种或多种。
6.根据权利要求1所述的保护化疗损伤肠黏膜屏障功能专用型临床营养配方,其特征在于,所述钙选自碳酸钙、葡萄糖酸钙、柠檬酸钙、L-乳酸钙、磷酸氢钙、氯化钙、磷酸三钙、甘油磷酸钙、氧化钙、硫酸钙中的一种或多种组成;所述钾选自葡萄糖酸钾、柠檬酸钾、磷酸二氢钾、磷酸氢二钾、氯化钾中的一种或多种;所述铁选自硫酸亚铁、葡萄糖酸亚铁、柠檬酸铁铵、富马酸亚铁、柠檬酸铁、焦磷酸铁中的一种或多种;所述锌选自葡萄糖酸锌、氧化锌、柠檬酸锌、硫酸锌、甘氨酸锌、乳酸锌、乙酸锌、碳酸锌中的一种或多种。
7.根据权利要求1所述的保护化疗损伤肠黏膜屏障功能专用型临床营养配方,其特征在于,所述所述药食同源成分选自桃仁、紫苏和葛根中的一种或多种。
8.根据权利要求1所述的保护化疗损伤肠黏膜屏障功能专用型临床营养配方,其特征在于,脂肪选自鱼油微囊粉、亚麻籽油微囊粉、月见草油微囊粉、橄榄油微囊粉、链甘油三酯粉、二十二碳六烯酸油脂粉、花生四烯酸油脂粉、茶油微囊粉中的一种或多种。
9.根据权利要求8所述的保护化疗损伤肠黏膜屏障功能专用型临床营养配方,其特征在于,所述脂肪中,不饱和脂肪酸n-6:n-3=4~6:1。
10.一种如权利要求1-9所述的保护化疗损伤肠黏膜屏障功能专用型临床营养配方的制备方法,其特征在于,包括以下步骤:
(1)预定重量的药食同源成分通过粉碎、醇提、水提、喷雾干燥并过60-80目筛制成粉末;
(2)按照组分表称量其他各组分,维生素、矿物质、新资源食品原料和步骤(1)制得的粉末混合制备预混料,将预混料与2%麦芽糊精先混合10分钟;
(3)将其它物料按照逐级递增的原则投入混合机,混合20分钟,出料,得配方制剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911083249.2A CN110720628A (zh) | 2019-11-07 | 2019-11-07 | 一种保护化疗损伤肠黏膜屏障功能专用型临床营养配方及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911083249.2A CN110720628A (zh) | 2019-11-07 | 2019-11-07 | 一种保护化疗损伤肠黏膜屏障功能专用型临床营养配方及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110720628A true CN110720628A (zh) | 2020-01-24 |
Family
ID=69225069
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911083249.2A Withdrawn CN110720628A (zh) | 2019-11-07 | 2019-11-07 | 一种保护化疗损伤肠黏膜屏障功能专用型临床营养配方及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110720628A (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111480839A (zh) * | 2020-03-26 | 2020-08-04 | 上海复旦奥医医学科技有限公司 | 一种骨癌专用型临床营养配方及其制备方法 |
CN111513332A (zh) * | 2020-05-31 | 2020-08-11 | 上海复旦奥医医学科技有限公司 | 大肠癌专用型临床营养配方及其制备方法 |
CN111903962A (zh) * | 2020-05-25 | 2020-11-10 | 上海复旦奥医医学科技有限公司 | 一种胃溃疡和十二指肠溃疡专用型临床营养配方及其制备 |
CN113575933A (zh) * | 2021-07-30 | 2021-11-02 | 桂林市人民医院 | 一种脑卒中吞咽障碍患者食用的复合肠内营养制剂及其制备方法与进食干预方法 |
CN113615831A (zh) * | 2021-08-31 | 2021-11-09 | 西安交通大学医学院第一附属医院 | 一种促进溃疡性结肠炎粘膜修复的临床营养组合物及其制备方法 |
CN115644451A (zh) * | 2022-09-30 | 2023-01-31 | 内蒙古伊利实业集团股份有限公司 | 一种矿物质组合物及其产品和应用 |
CN115736026A (zh) * | 2022-11-30 | 2023-03-07 | 内蒙古伊利实业集团股份有限公司 | 一种婴幼儿配方奶粉 |
-
2019
- 2019-11-07 CN CN201911083249.2A patent/CN110720628A/zh not_active Withdrawn
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111480839A (zh) * | 2020-03-26 | 2020-08-04 | 上海复旦奥医医学科技有限公司 | 一种骨癌专用型临床营养配方及其制备方法 |
CN111903962A (zh) * | 2020-05-25 | 2020-11-10 | 上海复旦奥医医学科技有限公司 | 一种胃溃疡和十二指肠溃疡专用型临床营养配方及其制备 |
CN111513332A (zh) * | 2020-05-31 | 2020-08-11 | 上海复旦奥医医学科技有限公司 | 大肠癌专用型临床营养配方及其制备方法 |
CN113575933A (zh) * | 2021-07-30 | 2021-11-02 | 桂林市人民医院 | 一种脑卒中吞咽障碍患者食用的复合肠内营养制剂及其制备方法与进食干预方法 |
CN113615831A (zh) * | 2021-08-31 | 2021-11-09 | 西安交通大学医学院第一附属医院 | 一种促进溃疡性结肠炎粘膜修复的临床营养组合物及其制备方法 |
CN113615831B (zh) * | 2021-08-31 | 2023-09-01 | 西安交通大学医学院第一附属医院 | 一种促进溃疡性结肠炎粘膜修复的临床营养组合物及其制备方法 |
CN115644451A (zh) * | 2022-09-30 | 2023-01-31 | 内蒙古伊利实业集团股份有限公司 | 一种矿物质组合物及其产品和应用 |
CN115736026A (zh) * | 2022-11-30 | 2023-03-07 | 内蒙古伊利实业集团股份有限公司 | 一种婴幼儿配方奶粉 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110720628A (zh) | 一种保护化疗损伤肠黏膜屏障功能专用型临床营养配方及其制备方法 | |
US11696921B2 (en) | Synthetic composition for microbiota modulation | |
EP2217246B1 (en) | Use of oligosaccharides containing n-acetyllactosamine for maturation of immune responses in neonates | |
JP5497634B2 (ja) | 術前及び/又は術後環境におけるプロバイオティックス | |
Serna-Thomé et al. | Use of functional foods and oral supplements as adjuvants in cancer treatment | |
EP3265099B1 (en) | Human milk oligosaccharides for treating acute respiratory tract infections | |
JP5462191B2 (ja) | 中鎖ジカルボン酸、その誘導体及び代謝異常 | |
JP2021504420A (ja) | 微生物叢調節のためのヒトミルクオリゴ糖およびその合成組成物 | |
US20150181916A1 (en) | Array of complementary infant/young child nutritional compositions | |
CN110226741A (zh) | 一种溃疡性结肠炎专用型临床营养配方及其制备方法 | |
CN110650635A (zh) | 出于健康目的而用于婴儿或幼儿的hmo共混物 | |
MX2013005364A (es) | Formula nutricional a la medida de la edad con densidad calorica particularmente adaptada para lactantes. | |
AU2016256709A1 (en) | Age-tailored nutritional composition with animal fats and vegetable fats | |
EP3307290B1 (en) | Dietary supplement | |
TW201208583A (en) | Nutritional compositions | |
CN111436601A (zh) | 一种胰腺癌专用型临床营养配方及其制备 | |
CN113632848A (zh) | 一种有利于骨骼增长的儿童奶粉及其制备方法 | |
CN110754656A (zh) | 一种淋巴肿瘤功能专用型临床营养配方及其制备方法 | |
ES2546262T5 (es) | Composición para emplear en la promoción de la absorción del magnesio y/o la retención del magnesio | |
US20240138462A1 (en) | Nutrition supplement for cancer patients | |
CN111513332A (zh) | 大肠癌专用型临床营养配方及其制备方法 | |
CN116548608B (zh) | 一种儿童全营养配方粉及其制备方法和应用 | |
AU2014243769A1 (en) | Prebiotic composition and method of its use | |
CN113508841A (zh) | 一种营养丰富的早茶 | |
CN110800996A (zh) | 一种妊娠呕吐专用型临床营养配方及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20200124 |
|
WW01 | Invention patent application withdrawn after publication |